(Q36463948)

14 August 2017

1 reference

title

Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

Sarita Dubey

1

1 reference

14 August 2017

Jill M Siegfried

series ordinal

2

1 reference

14 August 2017

Anne M Traynor

series ordinal

3

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Lancet Oncology Commission

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

416-424

1 reference

14 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Lung cancer in US women: a contemporary epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

ER beta: identification and characterization of a novel human estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Regulation of postnatal lung development and homeostasis by estrogen receptor beta.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Expression of estrogen receptors alpha and beta in human lung tissue and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Re: Endocrine factors and adenocarcinoma of the lung in women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Hormone replacement therapy and lung cancer risk: a case-control analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Estrogen replacement therapy and risk of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Nongenomically initiated steroid actions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

The plasma membrane estrogen receptor: nuclear or unclear?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

A transmembrane intracellular estrogen receptor mediates rapid cell signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Proximal events in signaling by plasma membrane estrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970693-3

7 January 2021

10.1016/S1470-2045(06)70693-3

Identifiers

DOI

1 reference

14 August 2017

1 reference